Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA
Executive Summary
Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.
You may also be interested in...
FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn
FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn
NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
FDA has received only 16 NDA submissions for new molecular entities thus far in fiscal 2002